Skip to main content
S&P 5007,623.68-0.52%DOW52,215.16-1.23%NASDAQ25,955.34-0.21%BTC$80,645.00-0.98%ETH$2,373.55-0.82%GOLD$4,010.00-1.24%OIL$103.44+3.99%
Smart Investors Daily
SID Premium
Revvity, Inc. logo

NYSE · RVTY

Revvity, Inc.

Healthcare · Medical - Diagnostics & Research

$158.77

Up+$1.48 (+0.94%)

Updated Oct 24, 2026, 3:21 AM

SID Score

6.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
12.32B
P/E ratio
51.31
Dividend yield
0.22%
52-week range
$81.22 – $166.25
Volume
1.11M
Avg. volume
1.43M

Price performance · RVTY

RVTY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 23, 2026

RVTY closed at $158.77 after 21 trading sessions, up 5.07% for the selected period.

Last close
$158.77
Period change
+5.07%
Period low
$149.06
Period high
$158.77
Daily close
View OHLC price history
RVTY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 23, 2026$156.35$159.05$152.73$158.771.11M
Oct 22, 2026$156.18$161.64$154.87$157.361.78M
Oct 21, 2026$154.44$159.48$152.71$156.612M
Oct 20, 2026$152.64$157.575$152.19$156.011.4M
Oct 19, 2026$153.89$156.8673$150.71$150.941.26M
Oct 16, 2026$154.44$155.50$151.61$152.641.34M
Oct 15, 2026$151.91$156.86$148.83$154.712.37M
Oct 14, 2026$154.26$158.00$151.45$152.122.02M
Oct 13, 2026$156.44$157.46$153.10$155.081.39M
Oct 12, 2026$153.74$156.33$153.46$155.611.12M
Oct 9, 2026$152.40$155.50$152.40$154.181.22M
Oct 8, 2026$152.04$152.54$146.70$152.161.46M
Oct 7, 2026$153.03$156.01$149.25$153.602.23M
Oct 6, 2026$161.62$166.25$151.45$153.302.68M
Oct 5, 2026$151.45$157.45$150.385$157.361.55M
Oct 2, 2026$149.94$153.375$148.55$151.531.24M
Oct 1, 2026$155.48$155.48$148.31$149.062.48M
Sep 30, 2026$153.49$158.28$152.81$152.894.46M
Sep 29, 2026$150.49$153.06$149.29$152.771.6M
Sep 28, 2026$148.97$151.05$148.12$151.021.5M
Sep 25, 2026$150.70$151.991$147.025$151.111.94M

Latest RVTY news

The latest Smart Investors Daily articles mentioning RVTY.

Stock researchCompany · Overview

RVTY research

Overview

Company profile and research snapshot.

Company profile

Revvity is a global life sciences and diagnostics company formed in 2023 following the rebranding of PerkinElmer. The company operates in two segments: life sciences, which provides reagents and instruments for biopharma and academic research, and signals software, and diagnostics, which offers tools in immunodiagnostics and newborn and reproductive health. Revvity's products and services are sold worldwide, with major markets in the US, Europe, and China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$110.25
Implied upside
—
Analysts
25
RVTY recent ratings
DateFirmRatingTarget
Oct 13, 2026TD CowenBuy—
Oct 7, 2026BarclaysEqual-Weight—
Oct 6, 2026William BlairOutperform—
Sep 4, 2026KeybancOverweight—
Sep 1, 2026RBC CapitalSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 15, 2026

Revvity (RVTY), What Is Drawing Fresh Attention Now?

Revvity (RVTY) is back on investor calendars after announcing third quarter 2026 results are due on 3 November, with earnings per share expected to be higher and fresh conference appearances scheduled soon after. Revvity’s share price has surged over the past quarter, with a 30 day share price return of 18.4% and a 90 day gain of 36.2%. The 1 year total shareholder return of 65.6% contrasts with a weaker 5 year total shareholder return that is still down 12.8%, suggesting momentum has...

Yahoo · Oct 15, 2026

Revvity (RVTY) Stock Could Be 12% Stretched On Cash Flow

Revvity has delivered a strong share price run over the past year, and the key issue now is whether that market enthusiasm lines up with the cash the business can realistically generate. With the stock recently closing at US$152.12, investors are asking if the current tag fairly reflects the company’s underlying cash flows or if expectations are stretching ahead of what the business can support. Over the past 12 months, Revvity has returned 65.6%, which puts real weight on the question of...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By